Company intelligence / Profile preview

En Ze Jia Shi Pharmaceutical

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

The company's controlled-release gliclazide tablet (for diabetes) received a patent through 2030 and has shown equivalent release in preclinical in vitro and in vivo models, aiming to improve efficacy/safety over standard oral gliclazide; clinical trials were planned to begin after 2012, regulatory approval targeted for 2014, but no updated results are available

Therapeutic areas: EndocrinologyPulmonologyCardiovascular
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on En Ze Jia Shi Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on En Ze Jia Shi Pharmaceutical.

Explore the full profile